Abstract

X-ray crystal and other structural analyses indicate that Ho(III) and every newly synthesized ligand can form a binuclear Ho(III) complex with a 1:1 metal-to-ligand stoichiometry by nine-coordination at the Ho(III) center. Every ligand acts as a dibasic tetradentate ligand, binding to Ho(III) through the phenolate oxygen atom, nitrogen atom of quinolinato unit and the C N group, −O–C N– group (enolized and deprotonated from O C–NH– group) of the aroylhydrazine side chain. One DMF molecule is binding orthogonally to the ligand-plane from one side to the metal ion, while another DMF and nitrate (bidentate) are binding from the other. Dimerization of this monomeric unit occurs through the phenolate oxygen atoms leading to a central planar four-membered (HoO) 2 ring. Investigations of DNA binding properties show that all the ligands and Ho(III) complexes can bind to Calf thymus DNA through intercalations with the binding constants at the order of magnitude 10 5–10 6 M −1, but Ho(III) complexes present stronger affinities to DNA than ligands. All the ligands and Ho(III) complexes may be used as potential anticancer drugs. Investigations of antioxidation properties show that all the ligands and Ho(III) complexes have strong scavenging effects for hydroxyl radicals and superoxide radicals but Ho(III) complexes show stronger scavenging effects for hydroxyl radicals than ligands.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call